tiprankstipranks
Trending News
More News >
STRATEC Biomedical AG (DE:SBS)
XETRA:SBS
Advertisement

STRATEC Biomedical (SBS) AI Stock Analysis

Compare
4 Followers

Top Page

DE:SBS

STRATEC Biomedical

(XETRA:SBS)

Select Model
Select Model
Select Model
Neutral 64 (OpenAI - 4o)
Rating:64Neutral
Price Target:
€28.00
▼(-8.35% Downside)
STRATEC Biomedical's overall stock score of 63.75 reflects moderate financial performance and a reasonable valuation. The company's operational efficiency and strong balance sheet are positive factors, but challenges in revenue growth and net income stability are significant risks. Technical analysis indicates a neutral to slightly bearish outlook, which tempers the overall score. The absence of earnings call and corporate events data limits additional insights.

STRATEC Biomedical (SBS) vs. iShares MSCI Germany ETF (EWG)

STRATEC Biomedical Business Overview & Revenue Model

Company DescriptionStratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
How the Company Makes MoneySTRATEC Biomedical generates revenue through multiple streams, primarily by providing automated diagnostic systems and associated consumables to healthcare organizations and laboratories. The company earns money from the sales of its proprietary analyzers and instruments, which are often sold in partnership with major diagnostic companies that utilize STRATEC's technology in their own products. Additionally, STRATEC benefits from recurring revenue through the sale of consumables that are required for the operation of its diagnostic systems. The company also engages in long-term contracts and collaborations with partners, which can include joint development projects and technology licensing agreements, further contributing to its revenue. Overall, STRATEC's business model is built on providing high-quality, reliable solutions that enable its customers to improve diagnostic processes and patient outcomes.

STRATEC Biomedical Financial Statement Overview

Summary
STRATEC Biomedical shows moderate financial performance with stable gross profit margins and improved operational efficiency. However, challenges in revenue growth and declining net income pose risks to sustained profitability. The balance sheet is strong with a stable equity ratio and improving leverage, but significant debt levels remain a concern. Cash flow performance is mixed, with improved operating cash flow but inconsistent free cash flow growth.
Income Statement
65
Positive
STRATEC Biomedical's income statement indicates moderate performance. The company has seen fluctuations in revenue, with a decline in total revenue over the past few years. Gross profit margin is relatively stable, but there is a decreasing trend in net profit. The EBIT and EBITDA margins show a slight improvement in recent years, suggesting operational efficiency. However, stagnant revenue growth and declining net income highlight potential challenges in sustaining profitability.
Balance Sheet
70
Positive
The balance sheet of STRATEC Biomedical reflects a strong equity base relative to its total assets, with a stable equity ratio. The debt-to-equity ratio is improving, indicating a healthier leverage position. However, the total debt level remains significant, which could pose risks if not managed properly. Return on equity has been decreasing, hinting at potential challenges in generating shareholder value.
Cash Flow
60
Neutral
STRATEC Biomedical's cash flow statement presents a mixed picture. Operating cash flow has improved significantly, but free cash flow growth is inconsistent, reflecting fluctuating capital expenditures. The operating cash flow to net income ratio has improved, indicating better cash conversion. However, free cash flow to net income ratio remains volatile, pointing to potential issues in sustaining cash generation.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue257.14M257.62M261.91M274.63M287.33M250.10M
Gross Profit77.96M76.39M64.84M79.49M87.71M68.99M
EBITDA45.08M47.34M43.16M57.53M66.52M56.72M
Net Income14.70M16.02M15.37M29.22M39.96M25.18M
Balance Sheet
Total Assets422.41M445.06M466.58M397.50M368.52M331.90M
Cash, Cash Equivalents and Short-Term Investments18.70M48.73M34.22M24.07M48.72M39.15M
Total Debt128.70M130.53M141.37M87.15M85.30M109.58M
Total Liabilities185.71M202.53M233.25M172.32M162.77M159.36M
Stockholders Equity236.70M242.53M233.33M225.18M205.76M172.54M
Cash Flow
Free Cash Flow10.98M30.52M2.00M-8.74M43.24M6.27M
Operating Cash Flow25.56M48.71M19.43M10.28M63.47M31.85M
Investing Cash Flow-16.16M-15.97M-44.16M-19.00M-20.13M-21.84M
Financing Cash Flow-21.09M-20.30M35.44M-14.11M-34.33M5.22M

STRATEC Biomedical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price30.55
Price Trends
50DMA
27.41
Positive
100DMA
26.82
Positive
200DMA
27.28
Positive
Market Momentum
MACD
0.80
Negative
RSI
65.72
Neutral
STOCH
61.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SBS, the sentiment is Positive. The current price of 30.55 is above the 20-day moving average (MA) of 28.36, above the 50-day MA of 27.41, and above the 200-day MA of 27.28, indicating a bullish trend. The MACD of 0.80 indicates Negative momentum. The RSI at 65.72 is Neutral, neither overbought nor oversold. The STOCH value of 61.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:SBS.

STRATEC Biomedical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
€1.09B12.206.82%3.09%-0.03%-14.15%
64
Neutral
€368.93M21.746.73%1.96%-1.64%22.60%
58
Neutral
€1.11B30.2316.31%2.83%9.42%9.54%
55
Neutral
€1.35B-61.384.97%0.10%-18.82%-113.85%
51
Neutral
€47.19M-3.65-88.19%-4.90%-69.80%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:SBS
STRATEC Biomedical
30.55
-10.80
-26.12%
DE:BIO
Biotest
38.00
-3.60
-8.65%
DE:BNN
B.R.A.I.N. Biotechnology Research and Information Network
2.28
-0.40
-14.93%
DE:DRW3
Draegerwerk AG & Co. KGaA
65.70
19.08
40.92%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
17.69
3.85
27.83%
DE:PUS
Pulsion Medical Systems
21.40
6.10
39.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 06, 2025